沃尔瑟姆，马萨诸塞州, Sept. 19, 2025 (GLOBE NEWSWIRE) -- 维泰瑞隆是一家处于临床阶段的全球化生物科技公司，致力于探索和开发用于治疗衰老相关疾病的变革性疗法。公司今日宣布，Endpoints News 已将维泰瑞隆列入 2025 年“Endpoints 11 – 最具潜力生物科技初创企业”榜单。 该年度评选旨在表彰展现出专业精神、战略聚焦能力，以及在当今商业环境中具有高成长潜力的生物科技初创企业。维泰瑞隆受邀参加了于 2025 年 9 月 18 日在波士顿举行的颁奖典礼并接受了该奖项。 “我们非常荣幸获得 Endpoint News 的这项殊荣，这充分体现了我们在科学创新上的卓越成就，”维泰瑞隆总裁兼首席执行官 Dr. Shefali Agarwal 表示，“依托深厚的研究能力，我们已建立起了一条强大的、针对多种疾病的临床研发管线。为加速推进临床项目，我们近期进一步拓展了全球布局，尤其是在美国新设立的行政总部。在董事会、主要投资方及约160名全球员工的鼎力支持下，我们坚信公司已做好充分准备，将持续发展壮大，为患者提供创新疗法，应对衰老相关的退行性疾病、需要支持性治疗的疾病，以 ...

Group 1 - On September 19, Junshi Biosciences-U executed a block trade of 1 million shares, amounting to 43.69 million yuan, with a transaction price of 43.69 yuan, reflecting a discount of 0.70% compared to the closing price of the day [2] - In the past three months, Junshi Biosciences-U has recorded a total of 11 block trades, with a cumulative transaction amount of 515 million yuan [2] - The closing price of Junshi Biosciences-U on the same day was 44.00 yuan, showing a decline of 3.78%, with a turnover rate of 2.48% and a total trading volume of 847 million yuan, indicating a net outflow of 114 million yuan in main funds for the day [2] Group 2 - Over the past five days, Junshi Biosciences-U has experienced a cumulative decline of 9.84%, with a total net outflow of funds amounting to 297 million yuan [2] - The latest margin financing balance for Junshi Biosciences-U is 1.422 billion yuan, which has increased by 78.759 million yuan over the past five days, representing a growth rate of 5.86% [2]

Domestic News - The Ministry of Commerce and nine other departments announced 20 measures to promote the expansion and upgrade of the "15-minute convenient living circle" by 2030, aiming to establish 100 pilot cities and create 10,000 well-structured living circles with a resident satisfaction rate of over 90% and a chain store rate of over 30% [1] - The Ministry of Ecology and Environment reported that China has built the world's largest carbon emissions trading market, covering over 60% of the country's carbon emissions, and has initiated a voluntary greenhouse gas reduction trading market [1] - The Ministry of Industry and Information Technology, along with other departments, issued a "Light Industry Stabilization Growth Work Plan (2025-2026)" to enhance the role of light industry in economic stability, with a focus on new growth points such as smart home products and sports leisure products [2] - The Ministry of Transport released a plan to build high-quality data sets for the transportation industry by 2030, aiming to improve data supply and support the development of intelligent transportation networks [2] - The Civil Aviation Administration reported that China's civil aviation achieved a total transportation turnover of 151.8 billion ton-kilometers in August, marking a year-on-year increase of 8% [3] Market Updates - The People's Bank of China announced adjustments to the 14-day reverse repurchase operations, which will now be conducted with fixed quantity and interest rate bidding [3] - The National Foreign Exchange Administration reported that in August 2025, banks settled 15,103 billion yuan and sold 14,058 billion yuan, with cumulative settlements from January to August reaching 113,938 billion yuan [3] - The China Automobile Industry Association is conducting an anti-discrimination investigation in response to the U.S. measures against China's integrated circuit sector, focusing on the impact on the automotive industry [4] Housing and Automotive Industry - Shanghai has optimized its housing property tax pilot policies, providing tax exemptions for high-level talents and first-time homebuyers under certain conditions [5] - Xiaomi Auto Technology has initiated a recall of 116,887 electric vehicles produced between February 6, 2024, and August 30, 2025, in compliance with regulations [5]

Core Viewpoint - The approval of BILDYOS and BILPREVDA by the European Commission marks a significant milestone for the company, enhancing its international presence and product influence in the market [1] Product Approval - BILDYOS (60mg/mL) is indicated for the treatment of osteoporosis in postmenopausal women and men at high risk of fractures, as well as for bone loss related to hormone ablation in prostate cancer patients and long-term systemic glucocorticoid treatment in adult patients at high risk of fractures [1] - BILPREVDA (120mg/1.7mL) is indicated for the prevention of skeletal-related events in adults with advanced bone malignancies and for the treatment of patients with giant cell tumors of bone that are unresectable or may lead to severe functional impairment post-surgery, including adults and skeletally mature adolescents [1] International Market Recognition - The approval in the EU follows the previous approval in the United States, representing further recognition of the company's products in major international markets, which will facilitate the company's internationalization efforts and enhance the global influence of its products [1]

格隆汇9月19日丨科伦博泰生物-B(06990.HK)公告，兹提述中国证券监督管理委员会于2019年11月14日 发布并于2023年8月10日进一步修订的《H股公司境内未上市股份申请「全流通」业务指引》。鉴于 《指引》，公司董事会已审议及批准公司若干股东所持公司不超过357万股内资股及464万股非上市外资 股拟实施全流通。 董事会已审议及批准若干建议修改本公司章程的决议案，以反映公司若干股东持有的本公司若干内资股 及非上市外资股完成全流通后的公司股本结构变动。建议修改将于H股全流通完成后生效。根据现行公 司章程第18条规定，建议修改毋须进一步经股东批准。 ...

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for five companies, including Guizhi Yan Pharmaceutical, which is undergoing a transition from private to public listing [1] - Guizhi Yan Pharmaceutical is required to clarify the compliance of its equity control structure and provide detailed information regarding share price changes in the 12 months prior to its application [1][2] - The company is also asked to explain the reasons why its beneficial owner, Shi Mingfeng, has not been recognized as a co-actual controller [1] Group 2 - Maius Pharmaceutical Technology, established in 2015 and headquartered in Shanghai, focuses on the research and development of innovative formulations and targeted small molecule drugs, particularly in oncology, immune system diseases, and anti-infection [3] - The company has developed a comprehensive R&D platform that integrates chemical drug screening and delivery, significantly enhancing drug development efficiency and precision [3] - Maius is set to achieve its strategic goal of going public on NASDAQ through a merger with DT Cloud Acquisition Corporation, with an overall valuation of $250 million [2]

Company News - SF Holding (06936.HK) reported a total revenue of 24.787 billion yuan from its express logistics business in August, representing a year-on-year growth of 7.86% [2] - Guohao Group (00053.HK) announced its annual results for the year ending June 30, 2025, with revenue of 24.4 billion HKD, a year-on-year increase of 9%, and a net profit of 4.03 billion HKD, up 13% year-on-year [2] - Jieli Trading Treasure (08017.HK) launched the Deep Trade AI Agent, an intelligent trading system [2] - Innovent Biologics (01801.HK) received approval from the National Medical Products Administration for Masitinib to be used for blood sugar control in adult patients with type 2 diabetes [2] - Datang New Energy Group (00559.HK) issued a profit warning, expecting an annual net profit of 30 to 35 million HKD [2] - Zhonghuan New Energy (01735.HK) plans to collaborate with Ant Blockchain Technology (Shanghai) in the fields of new energy digital assets and new energy artificial intelligence ecosystem [2] - Fuhong Hanlin (02696.HK) received approval from the European Commission for the HLX14 product for the treatment of osteoporosis in specific populations [2] - Zhaoyan New Drug (06127.HK) subscribed to a financial product from Industrial and Commercial Bank of China worth 40 million yuan [2] Buyback Activities - Tencent Holdings (00700.HK) repurchased 857,000 shares at a cost of 551 million HKD, with repurchase prices ranging from 638.5 to 647 HKD [2] - HSBC Holdings (00005.HK) spent approximately 160 million HKD to buy back about 1.49 million shares, with repurchase prices between 106.9 and 107.6 HKD [3] - Shango Holdings (00412.HK) repurchased 3.7 million shares at a cost of approximately 22.623 million HKD, with repurchase prices ranging from 6.08 to 6.2 HKD [3]

Core Viewpoint - Watson Bio's subsidiary has applied for clinical trials of a freeze-dried mRNA vaccine for herpes zoster, which has been accepted by the National Medical Products Administration [1] Group 1 - The vaccine is developed in collaboration with Fudan University and Shanghai Bluebird Biopharmaceuticals [1] - The mRNA vaccine technology platform is independently developed by Watson Bio and its partners [1] - The vaccine aims to stimulate the immune system to produce immunity against the herpes zoster virus for prevention purposes [1]

Core Viewpoint - The European Commission has approved two biosimilars of denosumab, BILDYOS and BILPREVDA, developed by Fuhong Hanlin and Organon, marking a significant milestone in expanding treatment options for osteoporosis and related conditions in Europe [1] Group 1: Product Approval - The approval includes BILDYOS (60 mg/mL) and BILPREVDA (120 mg/1.7 mL), which are biosimilars to PROLIA and XGEVA, respectively, covering all indications approved for the original products in the EU [1] - With this approval, Fuhong Hanlin now has a total of four products approved in the EU [1] Group 2: Market Impact - The approval is expected to enhance accessibility to critical bone health treatments for millions of European patients, particularly women who are more affected by osteoporosis [1] - The launch of these biosimilars supports the sustainability of the European healthcare system by providing more treatment options for conditions related to bone loss [1] Group 3: Strategic Partnership - The approval is a result of the collaboration between Fuhong Hanlin and Organon, which signed a licensing and supply agreement in 2022, granting Organon exclusive commercialization rights for these biosimilars outside of China [2]

Core Viewpoint - The European Commission has approved the marketing authorization for two biosimilars of denosumab, BILDYOS® and BILPREVDA®, developed by Fuhong Hanlin in collaboration with Organon, marking a significant milestone in expanding treatment options for osteoporosis and related conditions in Europe [1][2]. Group 1: Product Approval - The approval includes BILDYOS® (60 mg/mL) and BILPREVDA® (120 mg/1.7 mL), which are biosimilars to PROLIA® and XGEVA®, respectively, covering all indications approved for the original products in the EU [1]. - With this approval, Fuhong Hanlin now has a total of four products approved in the EU [1]. Group 2: Market Impact - The approval of BILDYOS and BILPREVDA is expected to enhance accessibility to critical bone health treatments for millions of European patients, particularly women who are more affected by osteoporosis [1]. - The launch of these biosimilars supports the sustainability of the European healthcare system by providing more treatment options for conditions related to bone loss [1]. Group 3: Strategic Partnership - The collaboration between Fuhong Hanlin and Organon, established through a licensing and supply agreement in 2022, grants Organon exclusive commercialization rights for these biosimilars outside of China [2]. - This partnership is seen as a significant achievement in meeting the needs of European patients and healthcare systems [1].